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Adoptive transfer of ex vivo expanded neu specific
polyfunctional T-cells secreting TNF-alpha (a), IFN-
gamma (g), and IL-17 (Th1/Th17) cells into tumor bear-
ing mice can result in complete resolution of disease as
compared to the use of neu specific Th1 (Lai et al 2009).
Murine antigen specific Th1/Th17 cells could be readily
expanded with IL-2 and IL-21 in culture, however, the
use of these cytokines resulted in successful expansion of
human tumor antigen specific T-cells in only a minority
of patients. We sought to identify ex vivo culture condi-
tions that would be suitable for the clinical expansion of
polyfunctional HER2 specific Th1/Th17 for therapeutic
infusion. PBMC, derived from the aphaeresis of patients
previously immunized with a HER2 vaccine, were stimu-
lated with HER2 peptides in the presence of different
cytokines to polarize Th17 cells, and then cultured with
different T-cell growth factors on Day4/8, and subse-
quently expanded with CD3/CD28 beads on Day 12 and
IL-2 for 12 days. We found that IL-1beta (b)/IL-6 gener-
ated higher number of IL-17 secreting CD4 cells before
CD3/CD28 activation. Other cytokine combinations,
including IL-1b/IL-6/IL-21, IL-1b/IL-6/anti-TGFb anti-
body, and IL-21 alone, failed to further increase IL-17
cells. A low dose of IL-2 alone added in the culture on
Day 4/8, following HER2 peptide and IL-1b/IL-6, gener-
ated a higher number of antigen specific IL-17 secreting
cells than the combinations of IL-2/IL-7 and IL-2/IL-7/
IL-15. In addition, exposure to IL1-b/IL-6 at the time of
antigen stimulation was superior to the cytokines added
on Day 4/8. Flow cytometric studies of the T-cells gener-
ated showed the generation of a Th1/Th17 phenotype,
including dual secreting IL-17 and TNF-a, IL-17 and
IFN-g, and triple secreting IL-17, IFN-g and TNF-a.
These data demonstrate a streamlined methodology,
easily adaptable to the clinic, for the generation of tumor
specific polyfunctional T-cells for therapeutic infusion.
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